Pharmacokinetic–pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age
- 29 September 2010
- Vol. 51 (10) , 1954-1962
Abstract
Summary: Purpose: To identify and validate the efficacious monotherapy dosing regimen for topiramate in children aged 2 to Methods: Several models were developed in pediatric and adult populations to relate steady‐state trough plasma concentrations (Cmin) of topiramate to the magnitude of clinical effect in monotherapy and adjunctive settings. These models were integrated to derive and support the monotherapy dosing regimen for pediatric patients.Key Findings: A two‐compartmental population PK model with first‐order absorption described the time course of topiramate Cminas a function of dosing regimen. Disposition of topiramate was related to age, body weight, and use of various concomitant antiepileptic drugs. The PK–PD model for monotherapy indicated that the hazard of time to first seizure decreased with increasing Cminand time since randomization. Higher baseline seizure frequency increased risk for seizures. Age did not significantly influence hazard of time to first seizure after randomization to monotherapy. For adjunctive therapy, the distribution of drug and placebo responses was not significantly different among age groups. Based on the available PK–PD modeling data, the dosing regimen expected to achieve a 65–75% seizure freedom rate after 1 year for pediatric patients age 2–10 years is approximately 6–9 mg/kg per day.Significance: This analysis indicated no difference in PK–PD of topiramate between adult and pediatric patients. Effects of indication and body weight on PK were adequately integrated into the model, and monotherapy dosing regimens were identified for children 2–10 years of age.Keywords
This publication has 20 references indexed in Scilit:
- Topiramate in older patients with partial‐onset seizures: A pilot double‐blind, dose‐comparison studyEpilepsia, 2008
- Topiramate Monotherapy in Newly Diagnosed Epilepsy in Children and AdolescentsJournal of Child Neurology, 2007
- Efficacy and Safety of Topiramate in Refractory Epilepsy of ChildhoodJournal of Child Neurology, 2005
- Randomized dose-controlled study of topiramate as first-line therapy in epilepsyActa Neurologica Scandinavica, 2005
- Modélisation et essais cliniques en pédiatrieTherapies, 2005
- Population pharmacokinetic studies in pediatrics: Issues in design and analysisThe AAPS Journal, 2005
- Topiramate Pharmacokinetics in Children and Adults with EpilepsyClinical Pharmacokinetics, 2005
- The Use of Antiepileptic Drugs—Principles and PracticeEpilepsia, 2004
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Anticonvulsant Serum Levels Are Useful Only If the Physician Appropriately Uses Them: An Assessment of the Impact of Providing Serum Level Data to PhysiciansEpilepsia, 1983